Keyphrases
Confidence Interval
87%
Overall Survival
83%
Cluster Randomized Trial
65%
Weight Loss
56%
Odds Ratio
53%
Pancreatic Cancer
49%
Pancreaticoduodenectomy
49%
Breast Cancer Survivors
45%
Prostate Cancer Risk
41%
Health Studies
41%
Diet Study
41%
NIH-AARP
41%
Quality of Life
41%
Tumor
41%
Cancer Patients
39%
Randomized Trial
38%
Alzheimer's Disease
37%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
36%
Neoadjuvant
36%
Randomized Controlled Trial
35%
Generalized Estimating Equations
35%
Clinical Outcomes
35%
Behavioral Weight Loss
35%
Obesity
34%
Chemotherapy
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Pancreatic Ductal Adenocarcinoma
32%
Recurrence-free Survival
30%
Body Mass Index
30%
Enhanced Recovery
30%
Good Health
30%
High Risk
29%
Cetuximab
28%
Relative Efficiency
28%
Hazard Ratio
28%
After Surgery
27%
Phase II Trial
27%
Randomized Clinical Trial
26%
Multivariate Analysis
25%
Obese Women
25%
Symptom Experience
25%
Gynecologic Cancer Survivors
25%
Non-small Cell Lung Cancer (NSCLC)
25%
Pancreatic Neuroendocrine Tumors (pNETs)
25%
Decision Aid
25%
Diffuse Large B-cell Lymphoma (DLBCL)
25%
Computational Imaging
25%
Stereotactic Body Radiation Therapy
25%
Nab-paclitaxel
24%
Comorbidity
24%
Medicine and Dentistry
Neoplasm
100%
Malignant Neoplasm
92%
Overall Survival
90%
Breast Cancer
53%
Pancreaticoduodenectomy
52%
Odds Ratio
52%
Clinical Trial
45%
Pancreas Adenocarcinoma
44%
Health Care Cost
38%
Radiation Therapy
37%
Computer Assisted Tomography
36%
Neuroendocrine Tumor
36%
Comorbidity
35%
Randomized Controlled Trial
35%
Recurrent Disease
35%
Diseases
35%
Body Mass Index
34%
Non Small Cell Lung Cancer
33%
Pancreas Cancer
32%
Nutrition
31%
Lung
31%
Quality of Life
29%
Progression Free Survival
29%
Lung Cancer
28%
Arm
27%
Recurrence Free Survival
27%
Paclitaxel
26%
Head and Neck Squamous Cell Carcinoma
26%
Lung Transplantation
25%
Acute Myeloid Leukemia
25%
Uterine Cancer
25%
Prognostic Factor
24%
Multivariate Analysis
23%
Gemcitabine
22%
Oral
22%
Primary Outcome
21%
Postoperative Complication
21%
Cetuximab
20%
Biological Marker
19%
Wart Virus
19%
Prevalence
19%
Colorectal Carcinoma
18%
Cancer
18%
Fibrosis
18%
Surgical Infection
18%
Cesarean Section
17%
Hazard Ratio
17%
Oncology
17%
Randomized Clinical Trials
17%
Tumor
16%